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ABSTRACT
Although hyperglycemia is a key therapeutic
focus in the management of patients with type
2 diabetes mellitus (T2DM), many patients
experience sub-optimal glycemic control.
Current glucose-lowering agents involve the
targeting of various body organs. Sodium
glucose co-transporter type 2 (SGLT2)
inhibitors target the kidney, reduce renal
glucose reabsorption, and increase urinary
glucose elimination, thus lowering glucose
blood levels. This review examines some of the
key efficacy and safety data from clinical trials
of the main SGLT2 inhibitors approved or
currently in development, and provides a
rationale for the use of SGLT2 inhibitors in the
treatment of T2DM.
Keywords: Anti-hyperglycemic agents;
Efficacy; Glucose homeostasis; Hyperglycemia;
Renal function; Safety; Sodium glucose co-
transporter type 2 inhibitors; Type 2 diabetes
mellitus
INTRODUCTION
Cardiovascular disease (CVD) is the major cause
of death in patients with diabetes mellitus
(DM); however, microvascular complications
(e.g., retinopathy, nephropathy, and
neuropathy) cause significant morbidity and
disability, such as visual impairment/blindness,
progressive renal impairment, and non-
traumatic amputations. Hyperglycemia
increases the risk of microvascular
complications, and improved control of
hyperglycemia reduces the risk of
microvascular complications. Adiposopathy
(i.e., positive caloric balance leading to
adipocyte hypertrophy, visceral fat
accumulation, ‘‘lipotoxicity’’, and subsequent
pathogenic adipocyte and adipose tissue
endocrine and immune responses) is often the
initial promoter of insulin resistance and,
therefore, of hyperglycemia [1]. However, once
H. Bays (&)
Louisville Metabolic and Atherosclerosis Research
Center (L-MARC), 3288 Illinois Avenue, Louisville,
KY 40213, USA
e-mail: hbaysmd@aol.com
Enhanced content for this article is
available on the journal web site:
www.diabetestherapy-open.com
123
Diabetes Ther (2013) 4:195–220
DOI 10.1007/s13300-013-0042-y
elevated glucose levels are present, chronic
hyperglycemia itself may worsen glucose
control by further promoting insulin resistance
and impairing pancreatic beta-cell function (via
a reduced beta-cell survival and mass, decreased
insulin gene transcription, and decreased
insulin synthesis and secretion) [2, 3], through
a process often termed glucotoxicity.
Hyperglycemia may also promote
macrovascular complications via direct and
indirect effects on vasculature similar to those
observed in atherosclerosis [4–7]. Finally,
hyperglycemia may further worsen the
adiposopathic dyslipidemia often associated
with type 2 DM (T2DM) [8–11].
DM is defined by hyperglycemia and, given
the proven health benefits of reducing
hyperglycemia, glucose control remains a key
therapeutic focus for the treatment of DM [12–
19], with glycosylated hemoglobin A1c (HbA1c)
being a commonly used measure of longer-term
glycemic control. Some studies are inconclusive
in determining the efficacy of intensive versus
standard glycemic control in reducing
macrovascular disease in T2DM [20–23].
However, one interpretation of the existing
data is that the potential benefit of intensive
versus less intensive (or ‘‘standard’’) glucose
control is dependent on the mechanism of
action of the antidiabetes agent, as well as the
speed and extent by which glucose lowering is
achieved [24]. The greatest potential for
macrovascular CVD benefit seems to be
achieved with antidiabetes agents having the
most favorable effects on CVD risk factors and
the least potential to promote hypoglycemia, as
well as when aggressive therapy is implemented
early in the disease process in younger
individuals with limited comorbidities.
The recommended HbA1c target of the
American Diabetes Association, the European
Association for the Study of Diabetes, and the
International Diabetes Federation is \7.0%
(53 mmol/mol) [25–27], which is applicable to
many non-pregnant adults with DM [25].
However, it is increasingly recognized that the
best health outcomes are often achieved via
individualization of DM treatment objectives
[26]. Less stringent HbA1c goals (such as\8.0%)
may be appropriate for some patient groups,
such as DM patients with hypoglycemia
unawareness, as well as individuals with
repeated bouts of severe hypoglycemia,
comorbid conditions, and advanced
microvascular/macrovascular complications
[25]. Conversely, if significant hypoglycemia
or other treatment side effects can reasonably be
avoided, then more stringent HbA1c goals (such
as 6.0–6.5%) might be considered in selected
patients with short disease duration, minimal to
no DM complications, and otherwise good
health [25].
The key point is that improved glucose
control in DM patients can reduce the risk of
microvascular disease, and possibly reduce
macrovascular disease in selected individuals.
However, in clinical practice, glycemic control
remains sub-optimal in many patients [28–32].
Data from the 2004 US National Health and
Nutrition Examination Survey revealed that
approximately 43% of DM patients had HbA1c
[7.0% [33]. Reasons for the failure to achieve
glycemic targets are multifactorial, and may
include issues relating to the health-care
provider (e.g., failure to sufficiently instruct on
lifestyle changes, reluctance to intensify
antidiabetes drugs, complexity of antidiabetes
drug management, or lack of expertise) [34],
and to the patient (e.g., non-adherence to
favorable lifestyle habits and other therapies,
lack of attendance at clinic, lack of
understanding of the disease, reluctance to use
insulin when required, longer duration of DM,
or younger age [\40 years]) [30, 31, 35, 36].
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Lifestyle modifications, such as nutritional
and physical activity interventions, remain
important toward improving both the glucose
levels and overall health of DM patients.
However, the reality is that the majority of
patients with DM are managed with glucose-
lowering therapeutic agents. Some examples of
target organs for agents that lower glucose
levels in DM include the pancreas, liver,
muscle, adipose tissue, gastrointestinal
system, and central nervous system. Due to
the potential DM complication of
nephropathy, the kidney has historically been
regarded solely as a ‘‘victim’’ in DM
management. With the development of the
sodium glucose co-transporter type 2 (SGLT2)
inhibitors, the kidney is now recognized as a
potential ‘‘ally’’ in the management of DM
[37]. Specifically, SGLT2 inhibitors reduce renal
glucose reabsorption and promote urinary
glucose excretion, thus lowering glucose
blood levels. This supports the concept of the
kidney as a target organ in the treatment of
DM.
This review examines kidney glucose
management and literature supporting SGLT2
inhibitors as a therapeutic approach to treating
hyperglycemia.
METHODS
The literature search involved review and
original articles published up to July 11, 2013
using PubMed, with key search terms
including SGLT2 inhibitors, sodium glucose co-
transporter 2 inhibitors, glucose and kidney, and
the individual drug names (dapagliflozin or
BMS-512148; canagliflozin or JNJ-24831754;
empagliflozin or BI10773; luseogliflozin or TS-
071; tofogliflozin or CSG452; ipragliflozin or
ASP1941; LX4211; EGT0001442; and
ertugliflozin or PF04971729). Other sources of
information for this review included abstracts
from the American Diabetes Association
(2010–2013) and the European Association
for the Study of Diabetes (2010–2012), and




Overview of Renal Structure and Function
The anatomy of the kidney is shown in Fig. 1.
The main structural and functional unit of the
kidney is the nephron. A normal human kidney
contains approximately 1 million nephrons,
with the majority located in the renal cortex
and the remainder situated near the cortico-
medullary junction. Each nephron consists of a
glomerulus, containing afferent and efferent
capillaries, and a renal tubule, which includes
the glomerular (or Bowman’s) capsule, proximal
convoluted tubule, loop of Henle, distal
convoluted tubule, and the collecting duct.
Higher positive pressure in the glomerular
blood vessels forces fluid and solutes from the
plasma into the glomerular capsule (filtration),
and this filtrate then flows through the renal
tubule. Much of this glomerular filtrate
undergoes reabsorption into capillary blood
via the proximal convoluted tubule.
Nitrogenous and other waste products largely
remain in the filtrate and pass into the
collecting duct, eventually leading to urinary
excretion. Other substances (e.g., hydrogen
ions, potassium ions, ammonia, and drugs)
undergo transport from peritubular capillaries
into the renal tubule cells, and then into the
filtrate for ultimate urinary excretion via the
ureter, bladder, and urethra.
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Physiology of Renal Glucose Transport
Key kidney functions that help achieve glucose
homeostasis involve renal gluconeogenesis,
glucose uptake from the circulation, and
glucose reabsorption from the glomerular
filtrate [38]. Given an average plasma glucose
concentration of approximately 100 mg/dL
(5.5 mmol/L) and a normal glomerular
filtration rate of approximately 180 L/day,
healthy individuals filter in the region of 180
g/day of glucose. Virtually all glucose is reabsorbed
in the proximal convoluted tubule and returned
to the circulation, so that effectively no glucose
is excreted in the urine of an otherwise healthy
individual. This system is highly efficient and
allows conservation of glucose, which is a
valuable energy source. Given the figure of
180 g/day of glucose reabsorbed, and the fact
that the kidneys produce 15–55 g/day of glucose
via gluconeogenesis and metabolize 25–35
g/day, renal absorption is a primary mechanism
by which the kidney influences glucose
homeostasis [38].
To retrieve glucose in the filtrate, the kidney
utilizes two types of membrane-bound carrier
proteins: SGLTs (sometimes described as
symporters because they transport both
glucose and sodium) and the facilitated
glucose transporters (GLUTs, sometimes
described as uniporters because they only
transport glucose) [39, 40]. Details of the SGLT
and GLUT families are given in Table 1 [40, 41].
Reabsorption of glucose from the glomerular
filtrate is mediated by SGLTs in the proximal
convoluted tubule (Fig. 2), in a process that is
independent of insulin. Approximately 90% of
filtered renal glucose is reabsorbed in the first
segment (S1) of the proximal convoluted tubule
by SGLT2, a low-affinity high-capacity
transporter, and the remaining 10% is
removed in the distal segment (S3) by SGLT1,
a high-affinity low-capacity transporter [39, 40].
In the kidney, SGLT2 and SGLT1 are located on
the luminal surface of epithelial cells lining the
proximal convoluted tubule [40]. SGLT2 is
expressed to a lower extent in other organs,
including the liver, while SGLT1 is extensively
Fig. 1 Renal anatomy. Nephrons are predominantly
located in the renal cortex, with the remainder at the
cortico-medullary junction. Each nephron consists of a
glomerulus, containing afferent and efferent capillaries, and
a renal tubule, including proximal and distal sections and a
collecting duct
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Known function Associated disease
Sodium glucose co-transporters (SGLT)
SGLT1 Intestine, trachea, kidney,
heart, brain, testis,
prostate
Active co-transport of sodium, glucose,
and galactose across intestinal brush
border and S3 segment of kidney
proximal tubule
SGLT1 mutations associated with
congenital glucose–galactose
malabsorption
SGLT2 Kidney, brain, liver,
thyroid, muscle, heart
Active co-transport of sodium and
glucose in S1 segment of kidney
proximal tubule
SGLT2 mutations associated with
familial renal glucosuria
SGLT3 Intestine, testis, uterus,
lung, brain, thyroid
Not a glucose transporter in humans—
probable glucosensor
Unknown
SGLT4 Intestine, kidney, liver,
brain, lung, trachea,
uterus, pancreas
Unknown—glucose, mannose substrates Unknown
SGLT5 Kidney cortex Unknown—glucose, galactose substrates Unknown
SGLT6 Brain, kidney, spinal cord,
small intestine
Unknown—d-chiro-inositol substrate Unknown
Facilitated glucose transporters (GLUT)
GLUT1 Ubiquitous Glucose transport GLUT1 deﬁciency contributes to
De Vivo disease (low
cerebrospinal ﬂuid glucose levels)
GLUT2 Pancreas, liver, kidney,
small intestine







Glucose transport in neurons (high
afﬁnity)
Unknown
GLUT4 Skeletal muscle, heart,
adipose tissue
Glucose transport (high afﬁnity) GLUT4 deﬁciency may cause
insulin resistance and diabetes
mellitus, as well as cardiac
hypertrophy
GLUT5 Intestine (kidney, brain,
fat, testis, muscle—lower
levels)
Fructose transport (and very low-afﬁnity
glucose transport)
Unknown
GLUT6 Spleen, leukocytes, brain Glucose transport Unknown
GLUT7 Small and large intestine Unknown Unknown
GLUT8 Testis, blastocyst, brain,
muscle, adipocytes
Glucose transport Unknown
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expressed in the small intestine, where it has a
significant role in glucose absorption [40].
SGLTs actively transport glucose against its
concentration gradient via coupling to the
electrochemical sodium gradient, using energy
from a sodium/potassium adenosine
triphosphatase pump [39, 40]. Glucose is
released from the proximal convoluted tubule
and returned to the bloodstream via GLUT2 in
the S1/S2 segment and via GLUT1 in the S3
segment of the proximal convoluted tubule [39,
40]. This is a passive process requiring no energy
(adenosine triphosphatase) input.
The amount of glucose filtered in the kidney
increases linearly with increasing plasma
glucose concentration until the transport
maximum for glucose is reached (abbreviated
as TMG and often expressed as mg glucose/min).
Beyond the level of the TMG, the glucose
transport system becomes saturated; therefore,
any excess glucose remains in the filtrate and is
excreted in the urine (i.e., glucosuria). In
healthy, glucose-tolerant individuals, TMG is
equivalent to a filtration rate of 260–350
mg/min [42]. The plasma glucose concentration
at which TMG is reached is called the renal
threshold, and occurs at approximately
200 mg/dL (11.0 mmol/L) [43]. This threshold
may vary between individual nephrons due to
variation in their activity and actual
reabsorption capacity, which may be below
the TMG level; the difference between the
theoretical and actual renal thresholds is
called ‘‘splay’’ [44].
Renal Glucose Handling in T2DM
In T2DM patients, glucose handling by the
kidney may be altered, with an increase in TMG
and urinary glucose excretion (UGE; i.e.,
glucosuria) at more elevated plasma glucose
levels [38]. Mean TMG may increase to up to
20% or higher in those with DM, compared
with healthy individuals [45]. Furthermore,
SGLT2 and GLUT2 expression may be up-






Known function Associated disease
GLUT9 Liver, kidney, intestine
(chondrocytes—low
levels)
Urate transporter Inactivating mutations of GLUT9
cause hypouricemia
GLUT10 Liver, pancreas Glucose transport GLUT10 mutations cause arterial
tortuosity syndrome
GLUT11 Heart, skeletal muscle Fructose and glucose transport Unknown




(Probable glucose homeostasis) Unknown
GLUT13
(HMIT)
Brain Myoinositol transport Unknown
GLUT14 Testis Probable glucose transport Unknown
Source: Information taken from Wright et al. [40] and Thorens and Mueckler [41]
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might be considered maladaptive in that they
attenuate glucosuria, resulting in enhanced
glucose reabsorption and further worsening
hyperglycemia [37]. Inhibiting this cycle
would be expected to increase glucose





Inhibiting SGLT2 provides an attractive addition
to the DM treatment armamentarium. SGLT2
inhibitors reduce the TMG, so less glucose is
reabsorbed in the proximal convoluted tubule;
they also lower the renal threshold, so UGE
occurs at a lower plasma glucose concentration
(Fig. 3 [48]). The net result is increased UGE and
decreased hyperglycemia. In addition to
potentially improving hyperglycemic
symptoms and DM disease complications,
normalization of plasma glucose concentration
may improve the adverse effects of
glucotoxicity, which may contribute to DM
itself, by reducing insulin resistance, decreasing
hepatic gluconeogenesis, and potentially
improving pancreatic beta-cell function [49].
Genetic models can often provide insight
into what might be expected with therapeutic
interventions. Individuals with familial renal
glucosuria (FRG) have mutations in the gene
encoding SGLT2 that cause loss of function.
FRG is characterized by UGE, varying from a few
grams to [200 g/day, depending on the
presence of a homozygous or heterozygous
mutation, in the presence of normal plasma
glucose concentrations and without evidence of
renal tubular dysfunction [50]. Most individuals
affected by FRG have no symptoms and only
rarely suffer from hypoglycemia or
hypovolemia [50]. The lack of adverse events
experienced by individuals with FRG due to
Fig. 2 Glucose transporters in the renal proximal tubule.
Data suggest approximately 90% of ﬁltered glucose is
reabsorbed in the ﬁrst part (S1) of the proximal tubule and
is mediated by SGLT2. The remaining 10% is reabsorbed
in the distal (S2/S3) part of the tubule and this is mediated
by SGLT1. This process is extremely efﬁcient and virtually
no glucose escapes into the urine of a healthy individual.
Glucose is returned to the bloodstream via GLUT2 in the
S1/S2 segment and via GLUT1 in the S3 segment of the
proximal tubule
Fig. 3 Renal glucose handling before and after SGLT2
inhibition. SGLT2 inhibition reduces the transport max-
imum for glucose (TMG), which decreases glucose reab-
sorption in the proximal renal tubule, and lowers the renal
threshold so that urinary glucose excretion (i.e., glucosuria)
occurs at a lower plasma glucose concentration (repro-
duced with permission from [48])
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persistent UGE suggests that long-term UGE
induced by pharmacologic inhibition of SGLT2
may also be well tolerated. However, the
number of FRG patients studied to date is
small and these patients typically did not have
DM. Therefore, while intriguing, long-term
safety data for any therapeutic agents based
upon this mechanism (i.e., SGLT2 inhibitors)
are required before any conclusions can be
made regarding the potential value of such
agents in the clinical management of DM.
SGLT2 INHIBITORS
Phlorizin is a naturally occurring glucoside
found in various plants, such as the root bark
of apple and other fruit trees, and was the
prototype SGLT2 inhibitor. The structure of
phlorizin is shown in Fig. 4. First isolated in the
1800s, research into phlorizin provided the
evidence that altered renal glucose excretion
could improve glycemic control [51, 52].
Studies from the 1950s revealed that phlorizin
blocked sugar transport in several tissues,
including the kidney and small intestine [53],
and this was subsequently found to be due to
inhibition of SGLT proteins. Phlorizin was
ultimately found to be a competitive inhibitor
of SGLT1 and SGLT2, but with a greater affinity
for SGLT2 [40, 51]. In the 1980s, investigators
found that phlorizin-induced UGE was effective
in reducing hyperglycemia via an insulin-
independent mechanism, without causing
hypoglycemia [54, 55]. Animal studies also
supported the use of phlorizin in improving
insulin sensitivity without affecting insulin
action in healthy control animals, with
hyperglycemia and insulin resistance both
returning after phlorizin discontinuation [54].
Unfortunately, phlorizin was unsuitable for
clinical development as a therapeutic agent for
a number of reasons. Firstly, phlorizin has a low
selectivity for SGLT2 versus SGLT1, resulting in
the inhibition of SGLT1 as well as SGLT2. As
SGLT1 is primarily expressed in the small
intestine, where it is responsible for the
absorption of glucose and galactose from the
diet, SGLT1 inhibition can result in
gastrointestinal side effects such as severe
diarrhea, dehydration, and malabsorption [40].
Secondly, phlorizin has a low oral
bioavailability and is metabolized to phloretin
by glucosidase enzymes in the gut, which
means it must be given parenterally. Lastly,
the phlorizin metabolite phloretin is a potent
inhibitor of GLUT1 [51], which may lead to
interference with glucose uptake in various
tissues (e.g., the central nervous system [41]).
Nonetheless, phlorizin served as a model
demonstrating how SGLT2 inhibition may
become a therapeutic target for hyperglycemia
[51]. Subsequent pharmacology research
focused on phlorizin derivatives that possess
increased stability, better bioavailability, more
potent SGLT2 selectivity, and which were more
suitable for once daily oral dosing with
acceptable tolerability. Such investigations
have included both O- and C-glucoside
compounds. The first reported SGLT2 inhibitor
was T-1095, an orally administered O-glucoside
pro-drug that was metabolized in the liver into
its active form, T-1095A [56]. Although T-1095
demonstrated increased SGLT2 selectivity and a
dose-dependent glucosuric effect in preclinical
studies [56], its non-selective SGLT1 inhibition
led to discontinuation. Other O-glucoside
compounds, such as sergliflozin, were
discontinued during phase 2 studies. Attention
then turned to the C-glucoside compounds,
which had the advantage of increased
metabolic stability (see below) [57].
SGLT2 inhibitor compounds in clinical
development are shown in Table 2 and the
chemical structures of those in phase 3 trials
202 Diabetes Ther (2013) 4:195–220
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are shown in Fig. 4. Dapagliflozin was approved
in the European Union in 2012, and is awaiting
the outcome of resubmission of an application
to the US Food and Drug Administration (FDA)
following a complete response letter. The FDA
approved canagliflozin in March 2013 and the
submission made to the European Medicines
Agency (EMA) is still under consideration.
Marketing applications for empagliflozin were
submitted to the FDA and EMA in March 2013,
while marketing applications for ipragliflozin,
luseogliflozin, and tofogliflozin were also
recently submitted to the Japanese regulatory
body.
Dapagliflozin is the most advanced of the
SGLT2 inhibitors in terms of clinical
development and, thus, has the largest
amount of published clinical data.
Fig. 4 SGLT2 inhibitors in late phase clinical development
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Publications for the other SGLT2 inhibitors are
more limited and largely consist of data
presented in scientific abstracts. A summary of
key efficacy data from completed phase 3 trials
and larger phase 2 trials using SGLT2 inhibitors
developed in the US/Europe are presented in
Table 3.
Dapagliflozin Overview
Dapagliflozin 1–50 mg orally once daily was
evaluated as monotherapy in previously
untreated patients with T2DM [58–60], or as
add-on combination therapy with metformin
[59, 61, 62], other oral anti-hyperglycemic
agents [63–65], or insulin-based therapy [66–
68]. Dapagliflozin significantly reduced HbA1c
and fasting plasma glucose (FPG) levels
(Table 3), with longer-term extension studies
(C100 weeks) supporting maintained efficacy
[61, 63, 68]. Dapagliflozin monotherapy
(2.5–50 mg/day for 12 weeks) in T2DM
patients resulted in the urinary excretion of
52–85 g/day glucose at the end of the study
period, compared with a loss of 6 g/day with
placebo or metformin [69]. Dapagliflozin also
reduced body weight, with an approximate 2 kg
loss versus placebo after 12 weeks [66] or
24 weeks [58, 61], 1–2 kg loss versus
comparator after 24 weeks [59], and 4 kg loss
versus comparator after 52 weeks [63]. Although
body weight increased when dapagliflozin was
co-administered with pioglitazone, the increase
was smaller than that of the placebo plus
pioglitazone group (0.69–1.35 kg vs. 2.99 kg,
respectively) [65].




Dapagliﬂozin Bristol Myers Squibb,
AstraZeneca
3 EMA approval given in November 2012; recent
NDA resubmission to FDA
Canagliﬂozin Janssen (Johnson & Johnson),
Mitsubishi Tanabe
3 FDA approval given in March 2013; EMA
decision awaited
Empagliﬂozin Boehringer Ingelheim, Lilly 3 Applications ﬁled with FDA (NDA) and with
EMA (MAA) in March 2013
Ipragliﬂozin Astellas, Kotobuki 3 Marketing approval ﬁled with Japanese regulatory
body in March 2013
Luseogliﬂozin Taisho 3 Marketing approval ﬁled with Japanese regulatory
body in April 2013
Tofogliﬂozin Chugai, Kowa, Sanoﬁ 3 Marketing approval ﬁled with Japanese regulatory
body in June 2013
Ertugliﬂozin
(PF04971729)
Pﬁzer, Merck & Co. 2 Not applicable
LX4211 Lexicon Pharmaceuticals 2 Not applicable
EGT0001442 Theracos 2 Not applicable
EMA European Medicines Agency, FDA Food and Drug Administration (United States), MAA marketing authorization
application, NDA New Drug Application, SGLT2 sodium glucose co-transporter
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In terms of safety and tolerability,
dapagliflozin was associated with a small
increase in the incidence of minor
hypoglycemic events (0–10.0%) compared
with the control group (placebo/comparator,
0.7–9.0%), although this was not statistically
significant [59, 63–65]. A trial using
dapagliflozin in combination with insulin
(with/without B2 oral anti-hyperglycemic
agents) reported slightly higher rates of
hypoglycemic events (dapagliflozin [total
groups] 56.6% vs. placebo 51.8%), but major
hypoglycemic episodes were comparable
between groups (dapagliflozin [total groups]
1.3% vs. placebo 1.0%) [67]. In another trial
report, patients receiving dapagliflozin added to
metformin experienced significantly fewer
hypoglycemic events (3.5%) compared with
glipizide plus metformin (40.8%; P\0.0001)
[63]. A safety analysis of 12 pooled placebo-
controlled trials (n[4,500) reported that
hypoglycemia was more common with
dapagliflozin than with placebo (10.7–16.3%
vs. 8.0%, respectively), and that imbalances in
individual studies were only observed when
dapagliflozin was combined with a sulfonylurea
or insulin [70, 71].
Dapagliflozin reduced systolic blood pressure
(SBP) by up to 5 mmHg, with no significant
increase in heart rate or occurrence of
orthostatic hypotension [58, 61–65, 67].
Rates of hypotension, dehydration, and
hypovolemia were similar in dapagliflozin
groups (1–2%) to those in the placebo/
comparator groups (0–1%) [58, 67, 70].
Dapagliflozin treatment was not associated
with an increased risk of acute renal toxicity
or deterioration of renal function [72]. The
dapagliflozin Summary of Product
Characteristics advises against its use in
patients receiving loop diuretics or who are
volume depleted, and recommends appropriate
monitoring if volume depletion is likely to
occur [73].
Symptoms suggestive of genital infection,
such as cutaneous fungal infections, and lower
urinary tract infection (UTI) were common
adverse events with dapagliflozin and were
reported more frequently compared with
placebo/comparator. Genital infection
occurred in 2–13% of patients receiving
dapagliflozin compared with 0–5% of those
receiving placebo/comparator, with women
affected more commonly than men [58, 61–
65, 67]. Most cases were not severe and
responded well to standard therapy. Lower
UTIs also occurred more frequently with
dapagliflozin (3.0–12.5%) than with placebo/
comparator (0–9.0%) [58, 61–65, 67]. None of
these events were serious, and all cases resolved
with standard antibiotic therapy. The pooled
safety analysis (n = 4,545) reported that genital
infections and UTIs were more common with
dapagliflozin than placebo, and between-group
differences were less marked for UTIs (genital
infection: 4.1–5.7% dapagliflozin vs. 0.9%
placebo; UTIs: 3.6–5.7% dapagliflozin vs. 3.7%
placebo) [74, 75].
Canagliflozin Overview
Canagliflozin 50–300 mg once daily and 300 mg
twice daily was evaluated as monotherapy in
previously untreated patients with T2DM [76],
or as add-on combination therapy with
metformin [77–79], other oral anti-
hyperglycemic agents [80–83], or insulin-based
therapy [84, 85]. Canagliflozin significantly
reduced HbA1c and FPG levels from baseline in
studies of 12–52 weeks’ duration, as shown in
Table 3, and modestly reduced body weight (up
to 2.9 kg compared with control groups) [76, 77,
84]. Reductions in SBP with canagliflozin, when
used as monotherapy and in combination,
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ranged from -0.8 to -6.8 mmHg [76, 78, 79,
82]. A recent pooled analysis of six phase 3
studies (n = 4,158; treatment duration not
stated) revealed that canagliflozin produced
modest reductions in SBP (-3.3 and
-4.5 mmHg for 100 and 300 mg, respectively)
relative to placebo [86].
The overall incidence of hypoglycemia was
low and rates were similar across canagliflozin
(2–6%), placebo (2–3%), and comparator (5%)
groups [76, 77, 84]; however, canagliflozin
groups (4.9–5.6%) reported lower rates of
hypoglycemia compared with glimepiride
(34.2%) [79]. Prescribing information for
canagliflozin states that rates of hypoglycemia
were higher when canagliflozin was
administered with insulin or sulfonylureas
[87]. Genital mycotic infections were higher
with canagliflozin (3–15%) versus placebo/
comparator (0–6%); these events were mild to
moderate in severity and none led to study
discontinuation [76, 77, 79–81]. As with
dapagliflozin, genital mycotic infections were
more common in women. Genital mycotic
infections with canagliflozin were also assessed
in a pooled analysis of four 26-week phase 3
studies (n = 2,313) [88]. Genital mycotic
infections were more common in canagliflozin
groups than placebo, occurring in 11% of
women and 4% of men, versus 3% and 1% in
the placebo groups, respectively. These events
were generally mild or moderate in severity and
were managed with standard treatments; in
addition, few such events led to study
discontinuation [10 cases, canagliflozin groups
(6 cases 100 mg, 4 cases 300 mg)]. In a larger
data set of eight phase 3 studies (n = 9,439) with
longer mean exposure (68 weeks of
canagliflozin, 64 weeks of placebo), the rate of
male genital mycotic infection was higher (8%
canagliflozin, 2% placebo) and was more
common in uncircumcised men (11% vs. 3%
in circumcised men) [88]. Reported UTI events
showed a similar trend. Higher rates of UTI
occurred in the canagliflozin groups
(2.3–12.0%) versus the placebo/comparator
groups (2.1–8.0%); the events were mild to
moderate in severity and responded to
standard treatment [76–82]. The pooled
analysis of four 26-week phase 3 studies
(n = 2,313) stated that UTIs occurred in 5.1%
of patients receiving canagliflozin (100 mg plus
300 mg groups) and in 4.0% of those receiving
placebo [89].
Empagliflozin Overview
Empagliflozin 1–50 mg once daily was
evaluated as monotherapy in previously
untreated patients with T2DM [90, 91], or as
add-on combination therapy with metformin
[92–95], other oral anti-hyperglycemic agents
[96], or insulin-based therapy [97]. As shown in
Table 3, empagliflozin significantly lowered
HbA1c, reduced FPG, and decreased body
weight (up to 2 kg vs. placebo). Empagliflozin
10 and 25 mg produced placebo-corrected
reductions in SBP of approximately 2–5 mmHg
after 24 weeks [91, 94, 95].
The rate of hypoglycemia was low with
empagliflozin monotherapy (0.4–1.8%), and was
comparable to placebo (0.4%) and comparator
(sitagliptin monotherapy 0.4%, metformin
monotherapy 7.1%) [91, 93]. The rate of
hypoglycemia was higher when empagliflozin
was given in combination therapy, particularly
in regimens containing sulfonylurea or insulin
(empagliflozin ? metformin 2.4–3.6% vs.
sitagliptin ? metformin 5.4% [93]; empagliflozin
? metformin 1.4–1.8% vs. placebo ? metformin
0.5% [95]; empagliflozin ? metformin ?
sulfonylurea 11.5–16.1% vs. placebo ?
metformin ? sulfonylurea 8.4% [94]; and
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empagliflozin ? insulin 36.1% vs. placebo ?
insulin 35.3% [97]).
UTI events after 24 weeks were reported in
8.3–10.3% of empagliflozin patients versus 8.0%
of those on placebo, and the rates of genital
infection events were 2.3–2.7% for
empagliflozin and 0.9% for placebo [94]. A
pooled analysis of safety data from four
24-week phase 3 trials (n = 2,477) examined
the effect of empagliflozin on UTIs and genital
infections [98]. The percentage of patients with
events consistent with a UTI was similar across
all groups (7.5% and 9.3% for empagliflozin 10
and 25 mg, respectively, vs. 8.2% for placebo);
however, more patients receiving empagliflozin
reported events consistent with genital
infection (4.2% and 3.6% for empagliflozin 10
and 25 mg, respectively, vs. 0.7% for placebo)
[98]. Both types of event were more common in
women than in men, and were more common
in patients with a history of UTI or genital
infection [98]. Nevertheless, of those who
reported events consistent with UTI or genital
infection, most experienced only one episode;
the episodes were generally mild in severity,
and very few led to study discontinuation [4
cases of UTI (placebo: 1 case; empagliflozin: 2
cases, 10 mg and 1 case, 25 mg); 3 cases of
genital infection (empagliflozin: 1 case, 10 mg;
2 cases, 25 mg)] [98].
Ipragliflozin Overview
Ipragliflozin is currently being developed in
Japan (Table 2). Ipragliflozin 50–300 mg once
daily was evaluated as monotherapy in
previously untreated patients with T2DM [99,
100], or as add-on combination therapy with
metformin [101] and other oral anti-
hyperglycemic agents [102], and showed
significant decreases in HbA1c and FPG versus
placebo over periods of 12–24 weeks.
Ipragliflozin monotherapy produced a placebo-
corrected weight loss of -1.47 kg after 16 weeks
[100]. After 12–16 weeks, SBP was reduced by
-3.2 to -4.3 mmHg with ipragliflozin
compared with placebo [100, 101].
Hypoglycemia was reported in 1.0–5.9% of
ipragliflozin dose groups versus 0–3.0% in the
placebo/comparator groups [101, 102]. During a
12-week study, UTIs were infrequent and were
reported in all treatment groups (placebo 6.1%
vs. ipragliflozin 1.4–6.9%) [101]. Genital
infections occurred with greater frequency in
the ipragliflozin versus placebo groups
(3.0–4.3% vs. 1.5%, respectively) [101].
Other SGLT2 inhibitors in clinical
development had few publications available at
the time of this review.
Other Issues
Currently available information on outcomes
such as stroke, heart attack, and other vascular
complications is limited, but larger studies with
cardiovascular end points are ongoing and will
provide data in 2017 onwards [103, 104]. The
Canagliflozin Cardiovascular Assessment Study
(CANVAS; NCT01032629) has recruited more
than 4,000 patients with T2DM and elevated risk
of CVD, while the Empagliflozin Cardiovascular
Outcome Event Trial (NCT01131676) has
recruited an estimated 7,000 patients to date
and the Dapagliflozin Effect on Cardiovascular
Events (NCT01730534) study has recently begun
recruitment (for further details of these trials see
ClinicalTrials.gov).
The potential relationship between SGLT2
inhibitors and neoplasia is also being
investigated. Although the overall proportion of
patients with malignant or unspecified tumors
was similar between those treated with
dapagliflozin (1.43%) and placebo/comparator
(1.30%), breast and bladder cancer events were
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more common with dapagliflozin [71]. The FDA
regulatory submission for dapagliflozin stated
that 9 cases of breast cancer were reported out of
4,287 patients receiving dapagliflozin compared
with no cases out of 1,941 patients in the placebo/
comparator group, and 7 cases of bladder cancer
were reported out of 4,310 patients receiving
dapagliflozin compared with no cases out of 1,962
patients in the placebo/comparator group [105].
Hematuria was documented before exposure to
dapagliflozin in 4 of the patients later found to
have bladder cancer, and the patients with breast
cancer had received dapagliflozin for\1 year (2/9
cases were diagnosed within 6 weeks of
dapagliflozin treatment initiation). Whether
these are chance findings or clinically relevant
concerns requires further study.
The incidence of breast or bladder tumor
events was low for canagliflozin and occurred at
a similar rate across treatment groups (breast
cancer 0.41% vs. 0.39% and bladder cancer
0.07% vs. 0.11% for canagliflozin vs. non-
canagliflozin groups, respectively) [106]. No
data on cancer cases from other SGLT2
inhibitor studies are currently available.
This overview was limited to major data from
late phase and/or large trials of those compounds
that are the most advanced along the drug
development pathway. Due to the emerging
nature of this field, full text journal
publications are limited for many of these agents.
CONCLUSIONS
SGLT2 inhibitors represent a therapeutic
approach in the treatment of T2DM that is
independent of insulin secretion and activity.
Clinical trials have supported the efficacy of
SGLT2 inhibitors as add-on therapy with
metformin, sulfonylureas, thiazolidinediones,
dipeptidyl peptidase-4 (DPP-4) inhibitors, or
insulin. SGLT2 inhibitors may also have a role
as monotherapy in patients who are intolerant
to metformin (e.g., due to gastrointestinal side
effects), as well as to potentially facilitate the
use of triple combinations of oral anti-
hyperglycemic agents (e.g., metformin ? DPP-4
inhibitor ? SGLT2 inhibitor).
SGLT2 inhibitors improve glycemic control in
T2DM, reducing HbA1c and FPG levels, and are
somewhat effective in reducing body weight and
blood pressure, which are also CVD treatment
targets for many patients with T2DM. SGLT2
inhibitors are generally well tolerated with few
serious adverse events reported to date. When
evaluated versus comparator groups, the
hypoglycemic episodes associated with SGLT2
inhibitors were mostly mild in severity and not
statistically significant. Among the more
common adverse events of these agents is an
increased risk of genital infections, which
appears to be more common in women.
Some data regarding SGLT2 inhibitors are
lacking. For example, little data exist on the use
of SGLT2 inhibitors in debilitated older patients
(especially those with central nervous system
dysfunction, decreased cognition, and/or
impaired thirst mechanisms) who may be at
risk of volume depletion, hypotension, and
electrolyte disturbances. Additional studies of
interest would also include patients with
varying degrees of renal impairment, given
that the action of these drugs depends upon
mechanisms involving glomerular filtration rate
and renal function, and data from several such
studies have been published or presented at
congresses [72, 81, 107].
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